Eton Pharmaceuticals has licensed U.S. rights to ASN-001, a late-stage topical gel targeting moderate infantile hemangiomas, a condition currently treated off-label with ophthalmic timolol. ASN-001 complements Eton's existing oral solution HEMANGEOL, potentially covering the full spectrum of infantile hemangioma patients. Phase II/III trials showed significant efficacy, with up to 56% elimination or near-elimination at 24 weeks. Eton plans to submit a New Drug Application in the second half of 2027, aiming for FDA approval and launch in 2028, targeting an estimated 20,000 to 30,000 patients annually and expanding its pediatric dermatology portfolio.
American Eagle Outfitters reported strong Q2 results with earnings per share of $0.79, far exceeding the $0.22 estimate, and revenue of $1.38 billion, slightly above expectations. The growth was driven by a 25% revenue increase from its Aerie and OFF...
AeroVironment reported a strong quarterly earnings per share (EPS) of $0.59, well above analyst expectations of $0.22, showing solid profitability. However, its revenue of $329.06 million fell short of the estimated $451.95 million, reflecting mixed ...
Kuehn Law is investigating Picard Medical Inc. for possible breaches of fiduciary duty by its officers and directors. The lawsuit alleges that insiders engaged in a fraudulent stock promotion scheme using social media misinformation and fake financia...
Caleres reported a strong Q3 2026 earnings per share (EPS) of $0.47, surpassing analyst expectations by 27%, signaling improved profitability. However, its revenue of $695.45 million slightly missed estimates despite a 5.6% year-over-year increase, d...
Listen Labs, a startup using voice AI for customer interviews, walked away from a signed $125 million Series C funding round led by Menlo Ventures. The funding likely fell through due to ongoing acquisition talks with Salesforce, which is considering...
